"The press has a real obsession with adult cell clones, and
were not at all interested in that, he says with a
shrug. But he doesnt fault them. Robl understands that the
best way to stir up public interest is to scare people about some
looming Armageddon. Robls equanimity stems from the
fact that these days he couldnt be happier. In a career
dominated by the hit-or-miss cloning of rabbits and cows, he now
has the chance to improve life for his own species. How might
people with diseases benefit from genetically altered cows? By
incorporating donor or transgenes from, say, human saliva or skin
cells, into the nuclei of cow eggs, Robl is quite likely, and
soon, to be able to clone cows that produce therapeutic human
proteins. In other words, all those years of micropipetting nuclei,
nudging them into rubbery host cell membranes and electronically
stimulating the resulting eggs which may or may not grow, repeating
the process so many times he compares himself to an old lady with
her knitting, Robl may be doing work that greatly benefits his
fellow man. Picture it: the cow as drug dispensary. Thats
what scientists believe will happen when they replace the genes
that code for cow proteins in milk with human ones such as antibodies,
clotting factors, hemoglobin, even red blood cells, all of which
are now isolated at great cost from the precarious donor blood
supply. Combined with genetic engineering, cloning may bring us
into an age when cows (or pigs, or sheep) will do the work of
blood banks, possibly even functioning as repositories of transgenic
tissues for human transplant. Some day soon transgenic, cloned
cows might be sources for replacement heart tissue, new blood
vessels, or healthy nerve cells to cure Parkinsons disease,
says Robl, who has formed collaborations with scientists as far
away as Norway. I would love to see a therapeutic on the
market as soon as possible, he adds. Were pushing
very hard for that.
When
we started cloning our only objective was to pick a high-producing
cow and make copies of it, says Robl. We had no notion
wed be getting into human therapeutics. Sure, hes
the target of some vociferous criticism. But we mostly get
letters from people with diseases cheering us on. And how
does that feel? Its wonderful, says Robl, heading
back to work.